Cargando…

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib

Over the last decades, a better understanding of breast cancer heterogeneity provided tools for a biologically based personalization of anticancer treatments. In particular, the overexpression of the human epidermal growth factor receptor 2 (HER2) by tumor cells provided a specific target in these H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kourie, Hampig Raphael, El Rassy, Elie, Clatot, Florian, de Azambuja, Evandro, Lambertini, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513878/ https://www.ncbi.nlm.nih.gov/pubmed/28744140 http://dx.doi.org/10.2147/OTT.S122397

Ejemplares similares

Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2023)

Immunotherapies in sarcoma: Updates and future perspectives
por: Ghosn, Marwan, et al.
Publicado: (2017)

Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review
por: Kourie, Hampig Raphael, et al.
Publicado: (2015)

Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer
por: Miles, Jennifer, et al.
Publicado: (2018)

Oncofertility counselling in premenopausal women with HER2-positive breast cancer
por: Lambertini, Matteo, et al.
Publicado: (2019)

The impact of the coronavirus pandemic on the management of cancer patients in Lebanon: a single institutional experience
por: Kattan, Clarisse, et al.
Publicado: (2020)

Vulvar Metastasis from Bladder Cancer
por: Aoun, Fouad, et al.
Publicado: (2015)

Dilemma of first line regimens in metastatic pancreatic adenocarcinoma
por: Ghosn, Marwan, et al.
Publicado: (2016)

Twenty years of anti-HER2 therapy-associated cardiotoxicity
por: Pondé, Noam F, et al.
Publicado: (2016)

Neratinib for HER2-positive breast cancer with an overlooked option
por: Guo, Liting, et al.
Publicado: (2023)

Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature
por: Ghosn, Marwan, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
por: Tran, Phuong T., et al.
Publicado: (2020)

Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
por: Mehanna, Joe, et al.
Publicado: (2019)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
por: Alkhezayem, Sara, et al.
Publicado: (2020)

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Neratinib for Extended Anti-HER2 Therapy in Early Breast Cancer
por: Budd, G. Thomas, et al.
Publicado: (2018)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
por: Lambertini, Matteo, et al.
Publicado: (2018)

Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital
por: Cunningham, Niamh, et al.
Publicado: (2022)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
por: Eli, Lisa D., et al.
Publicado: (2022)

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
por: Chow, L W-C, et al.
Publicado: (2013)

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer
por: Chan, Arlene, et al.
Publicado: (2022)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
por: Untch, Michael, et al.
Publicado: (2021)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
por: Brandão, Mariana, et al.
Publicado: (2020)

Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?
por: Poggio, Francesca, et al.
Publicado: (2018)

How I treat metastatic triple-negative breast cancer
por: Caparica, Rafael, et al.
Publicado: (2019)

Neratinib for breast cancer
Publicado: (2019)

Complete Disappearance of Choroidal Metastasis from Lung Adenocarcinoma Treated with Bevacizumab and Chemotherapy
por: Kourie, Hampig Raphael, et al.
Publicado: (2015)

Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature
por: Kruse, Megan L., et al.
Publicado: (2021)

Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review
por: Simon, Aurélien, et al.
Publicado: (2017)

Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

Targeted therapies for cancer during the COVID-19 pandemic: a threat or a blessing?
por: Moujaess, Elissar, et al.
Publicado: (2020)

Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence
por: Moujaess, Elissar, et al.
Publicado: (2020)

Cancer management during the COVID-19 pandemic: Choosing between the devil and the deep blue sea
por: Boutros, Marc, et al.
Publicado: (2021)

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
por: Harding, James J., et al.
Publicado: (2023)

Treating cancer patients in times of COVID-19 pandemic: A virtual women cancers multidisciplinary meeting experience
por: Elkaddoum, Ronaldo, et al.
Publicado: (2020)

Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU
por: Dhillon, Sohita
Publicado: (2019)

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
por: Chilà, Giovanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2chqq32aahcfs3nl4ei0qr236g